REVIEWS

1051  Attacking a Nexus of the Oncogenic Circuitry by Reversing Aberrant eIF4F-Mediated Translation
Peter B. Bitterman and Vitaly A. Polunovsky

1062  Immunotherapy of Cancer with 4-1BB
Dass S. Vinay and Byoung S. Kwon

THERAPEUTIC DISCOVERY

1071  Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition

1082  Hyperactivation of 4E-Binding Protein 1 as a Mediator of Biguanide-Induced Cytotoxicity during Glucose Deprivation
Junichi Matsuo, Yoshinori Tsukumo, Sakae Saito, Satomi Tsukahara, Junko Sakurai, Shigeo Sato, Hiromichi Kondo, Masaru Ushijima, Masaaki Matsuura, Toshiki Watanabe, and Akihiro Tomida

1092  Off-Target Function of the Sonic Hedgehog Inhibitor Cyclopamine in Mediating Apoptosis via Nitric Oxide-Dependent Neutral Sphingomyelinase 2/Ceramide Induction
Marisa Meyers-Needham, Jocelyn A. Lewis, Salih Cencer, R. David Sentelle, Sahar A. Saddoughi, Christopher J. Clarke, Yusuf A. Hannun, Haakan Norrell, Telma Martins da Palma, Michael Nishimura, Jacqueline M. Kraveka, Zohreh Khavandgar, Monzur Murshed, M. Ozgur Cevik, and Besim Ogretmen

PRECLINICAL DEVELOPMENT

1103  Evading Pgp Activity in Drug-Resistant Cancer Cells: A Structural and Functional Study of Antitubulin Furan Metotica Compounds
Tam Luong Nguyen, Maria Rosaria Cera, Andrea Pinto, Leonardo Lo Presti, Ernest Hamel, Paola Conti, Rick Gussio, and Peter De Wulf

1112  JAK–STAT and JAK–PI3K–mTORC1 Pathways Regulate Telomerase Transcriptionally and Posttranslationally in ATL Cells
Osamu Yamada, Kohji Ozaki, Masaharu Akiyama, and Kiyotaka Kawauchi
miRNA-29b Suppresses Prostate Cancer Metastasis by Regulating Epithelial–Mesenchymal Transition Signaling
Peng Ru, Robert Steele, Philip Newhall, Nancy J. Phillips, Karoly Toth, and Ratna B. Ray

Therapeutic Significance of Estrogen Receptor β Agonists in Gliomas
Gangadhar R. Sareddy, Binoj C. Nair, Vijay K. Goonugunta, Quan-guang Zhang, Andrew Brenner, Darrell W. Brann, Rajeshwar Rao Tekmal, and Ratna K. Vadlamudi

Multiple Antigenic Peptides Based on H-2Kb-Restricted CTL Epitopes from Murine Heparanase Induce a Potent Antitumor Immune Response In Vivo
Xu-Dong Tang, Guo-Zhen Wang, Jun Guo, Mu-Han Lu, Chuan Li, Ning Li, Ya-Ling Chao, Chang-Zhu Li, Yu-Yun Wu, Chang-Jiang Hu, Dian-Chun Fang, and Shi-Ming Yang

Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer
Terence M. Williams, Athena R. Flecha, Paul Keller, Ashwin Ram, David Karnak, Stefanie Gabbana, Craig J. Gabbana, Brian D. Ross, Theodore S. Lawrence, Alnawaz Rehemtulla, and Judith Sebolt-Leopold

Retraction in Part: A Genomic Approach to Identify Molecular Pathways Associated with Chemotherapy Resistance

Correction: Narciclasine, a Plant Growth Modulator, Activates Rho and Stress Fibers in Glioblastoma Cells

About the Cover
Several allosteric MEK inhibitors are in clinical development and have been designed to treat patients with tumors harboring RAS/RAF pathway alterations. Acquired resistance to this class of inhibitors is a pressing clinical problem. To identify strategies to overcome this resistance, Hatzivassiliou and colleagues derived and characterized three independent MEK inhibitor-resistant cell lines. All of the resistant cell lines harbored mutations in the allosteric binding pocket of MEK that is targeted by arylamine MEK inhibitors. In all cases the MEK resistant cell lines retained their addiction to the MAPK pathway and remained sensitive to a selective inhibitor of the ERK1/2 kinases, suggesting a role for ERK inhibitors in combating or preventing MEK inhibitor resistance. For details, see article by Hatzivassiliou and colleagues on page 1143.